Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Vertex Pharmaceuticals Inc., income statement, revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
TRIKAFTA/KAFTRIO 8,944,700 7,686,800 5,697,200 3,863,824 420,105
KALYDECO 475,500 553,200 684,200 802,870 991,062
ORKAMBI 326,000 510,700 771,600 907,512 1,331,891
SYMDEKO/SYMKEVI 123,000 180,000 420,400 628,577 1,417,668
Product revenues, net 9,869,200 8,930,700 7,573,400 6,202,783 4,160,726

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Product revenues, net Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Vertex Pharmaceuticals Inc. product revenues, net increased from 2021 to 2022 and from 2022 to 2023.